Concepedia

Jill Drake

JD

26

Publications

1.5K

Citations

19

H-Index

2006

Active since

Affiliations

University of Otago(Current)

Christchurch Hospital

University of Auckland

Canterbury Health Laboratories

Dunedin Public Hospital

Jill Drake is an author at University of Otago specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

2006–2024

26

Publications

26

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol

Lisa K. Stamp, William J. Taylor, Peter B. Jones et al. · Arthritis & Rheumatism · 2012 · 285 citations

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study*

Alun Cooper, Jill Drake, E. Brankin · International Journal of Clinical Practice · 2006 · 153 citations · Full text

, , +16

A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout

Lisa K. Stamp, Peter T. Chapman, Murray L. Barclay et al. · Annals of the Rheumatic Diseases · 2017 · 145 citations

Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual‐Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial

Nicola Dalbeth, Karen Billington, Anthony Doyle et al. · Arthritis & Rheumatology · 2019 · 96 citations

ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout

R.L. Roberts, M C Wallace, Amanda Phipps‐Green et al. · The Pharmacogenomics Journal · 2016 · 91 citations

, , +7

Rows per page

1–5 of 26